EX-99.1 2 tm2428673d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Cautionary Note Regarding Forward-Looking Statements

 

This offering memorandum contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs and sources of liquidity.

 

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

 

·changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;

 

·adverse economic conditions including an inflationary environment could cause us to continue to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;

 

·shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit our ability to staff our facilities;

 

·shortages in qualified health professionals could cause us to increase our dependence on contract labor, increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase our operating costs significantly;

 

·public threats such as a global pandemic, or widespread outbreak of an infectious disease, similar to the COVID-19 pandemic, could negatively impact patient volumes and revenues, increase labor and other operating costs, disrupt global financial markets, and/or further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;

 

·the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;

 

·the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;

 

·a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

 

·acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

 

·our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;

 

·failure to complete or achieve some or all the expected benefits of the potential separation of Concentra;

 

·private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;

 

 

 

 

·the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;

 

·competition may limit our ability to grow and result in a decrease in our revenue and profitability;

 

·the loss of key members of our management team could significantly disrupt our operations;

 

·the effect of claims asserted against us could subject us to substantial uninsured liabilities;

 

·a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and

 

·other factors discussed under the heading “Risk factors” herein or incorporated by reference from our annual report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 22, 2024.

 

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

 

 

 

 

SUMMARY UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

 

The summary unaudited pro forma consolidated financial data below has been derived from our unaudited pro forma consolidated financial information included in the section of this offering memorandum entitled “Unaudited Pro Forma Consolidated Financial Information.” The unaudited pro forma consolidated financial information has been derived from our historical unaudited condensed consolidated statement of operations for the nine months ended September 30, 2024, our historical audited consolidated statement of operations for the year ended December 31, 2023, and our historical unaudited condensed consolidated balance sheet at September 30, 2024.

 

The unaudited pro forma consolidated financial data below is only a summary and should be read in conjunction with the section of this offering memorandum entitled “Unaudited Pro Forma Consolidated Financial Information.” The unaudited pro forma consolidated financial data is based upon available information and assumptions that we believe are reasonable and supportable. The summary unaudited pro forma consolidated financial data is for illustrative and informational purposes only. The summary unaudited pro forma consolidated financial data may not necessarily reflect what our financial condition, results of operations or cash flows would have been had we completed the divestiture of our Concentra segment during the periods presented. In addition, the summary unaudited pro forma consolidated financial data may not necessarily reflect what our financial condition, results of operations and cash flows may be in the future.

 

Pro Forma Consolidated Statement of Operations Data

 

   For the Nine Months Ended
September 30,		   Year ended December 31, 
(Dollars in thousands)  2024   2023 
Revenue  $3,874,541   $4,825,977 
Costs and expenses:          
Cost of services, exclusive of depreciation and amortization   3,379,931    4,254,369 
General and administrative   144,103    170,193 
Depreciation and amortization   106,583    135,691 
Total costs and expenses   3,630,617    4,560,253 
Other operating income   3,300    1,518 
Income from operations   247,224    267,242 
Other income and expense:          
Loss on early retirement of debt   —    (35,353)
Equity in earnings of unconsolidated subsidiaries   53,481    41,339 
Interest (expense) income   (63,274)   18,454 
Income before income taxes   237,431    291,682 
Income tax expense   61,928    69,568 
Net income   175,503    222,114 
Less: Net income attributable to non-controlling interests   51,306    51,444 
Net income attributable to Holdings  $124,197   $170,670 

 

Pro Forma Consolidated Balance Sheet Data

 

     
(Dollars in thousands)  As of September 30, 2024 
Total assets  $5,510,682 
Total liabilities  $3,511,470 
Total equity  $1,986,879 

 

 

 

 

Pro Forma Credit Statistics

 

(Dollars in thousands) 

As of or for the Twelve
Months Ended September 30, 2024(1)

 
Cash interest expense(2)  $104,844 
Total debt(3)  $1,658,721 
Net debt(4)  $1,631,399 
Net senior secured debt(5)  $732,678 
Ratio of Pro Forma Adjusted EBITDA to Pro Forma cash interest expense(6)   4.83x
Ratio of net senior secured debt to Pro Forma Adjusted EBITDA(6)   1.45x
Ratio of net debt to Pro Forma Adjusted EBITDA(6)   3.22x

 

 

(1) As of September 30, 2024, after giving pro forma effect to the incurrence of indebtedness in an aggregate principal amount equal to $1,600.00 million pursuant to the Refinancing Transactions.

 

(2) Calculated to give pro forma effect to the interest expense on the approximately $1,600.0 million of indebtedness expected to be incurred in connection with the Refinancing Transactions, as well as existing Other Debt of $48.7 million, as if such indebtedness had been incurred as of October 1, 2023 at an estimated weighted average interest rate of approximately 6.4%, excluding debt issuance costs and original issue discount. A variance of 1/8% of the weighted average interest rate estimate would result in a $2.0 million change in annual cash interest expense associated with the $1,600.0 million of indebtedness expected to be incurred.

 

(3) Consists of $1,600.0 million of indebtedness (including the Notes offered hereby) expected to be incurred pursuant to the Refinancing Transactions, $10.0 million of indebtedness outstanding under our revolving credit facility, and $48.7 million of indebtedness comprised primarily of notes payable, insurance financing arrangements and finance leases.

 

(4) Consists of total debt principal less pro forma cash of approximately $27.3 million as of September 30, 2024.

 

(5) Consists of total senior secured debt principal less pro forma cash of approximately $27.3 million as of September 30, 2024.

 

(6) Pro Forma Adjusted EBITDA for the trailing twelve months ended September 30, 2024, is $506.2 million which is calculated as Historical Select Medical Holdings Corporation trailing twelve month Adjusted EBITDA of $873.8 million less Concentra Adjusted EBITDA of $367.6 million.

 

Other Pro Forma Data (Non-GAAP)

 

   Nine Months Ended September 30   Year Ended December 31, 
(Dollars in thousands)  2024   2023 
Pro Forma Adjusted EBITDA(1)  $394,402   $446,091 
Pro Forma Adjusted EBITDA margin(1)   10.2%   9.2%

 

 

(1)We believe that the presentation of Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin, as defined herein, are important to investors because Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin, or equivalents thereto, are commonly used as an analytical indicator of performance by investors within the healthcare industry. Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are not measures of financial performance under GAAP. Items excluded from Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are not measurements determined in accordance with GAAP and are thus susceptible to varying definitions, Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies.

 

 

 

 

The following table reconciles Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin to Pro Forma Net income and should be referenced when we discuss Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin. For a reconciliation of Pro Forma Net income to Net income, see “Unaudited Pro Forma Consolidated Financial Information.”

 

   Nine Months Ended September 30,   Year Ended December 31, 
(Dollars in thousands)  2024   2023 
Reconciliation of Pro Forma Adjusted EBITDA to Pro Forma Net income          
Pro Forma Net Income  $175,503   $222,114 
Pro Forma Income tax expense   61,928    69,568 
Pro Forma Interest expense   63,274    (18,454)
Pro Forma Equity in losses of unconsolidated subsidiaries   (53,481)   (41,339)
Pro Forma Loss on early retirement of debt   –    35,353 
Pro Forma Income from Operations   247,224    267,242 
Pro Forma Stock compensation expense   38,899    43,158 
Pro Forma Depreciation and amortization   106,583    135,691 
Pro Forma Separation transaction costs   1,696    – 
Pro Forma Adjusted EBITDA  $394,402   $446,091 
Pro Forma Adjusted EBITDA margin   10.2%   9.2%
Pro Forma Net Income Margin   4.5%   4.6%

 

 

 

 

CAPITALIZATION

 

The following table sets forth our consolidated cash and cash equivalents and capitalization as of September 30, 2024:

 

·on a pro forma basis as derived from our historical audited consolidated financial statements incorporated by reference into this offering memorandum and giving effect to the Separation; and

 

·on a pro forma as adjusted basis to give effect to the Separation and to the Refinancing Transactions.

 

The cash and capitalization information in the following table may not necessarily reflect what our cash and capitalization would have been had we completed the Separation as of September 30, 2024. In addition, the cash and capitalization information in the following table may not necessarily reflect what our cash and capitalization may be in the future. The pro forma information set forth in the table below is illustrative only and will adjust based on the actual terms of this offering determined at the time of the pricing of this offering.

 

The following table should be read in conjunction with the sections of this offering memorandum entitled “Summary Unaudited Pro Forma Consolidated Financial Data,” “Use of Proceeds” and “Unaudited Pro Forma Consolidated Financial Information” as well as our historical audited consolidated financial statements included elsewhere in this offering memorandum.

 

   As of September 30, 2024 
(Dollars and share amounts in thousands) (unaudited)  Pro Forma   Pro Forma
As Adjusted		 
Cash and cash equivalents  $54,646   $27,322 
Debt:          
Existing Select Term Loan   372,982    – 
New Select Term Loan   –    750,000 
Senior secured revolving facility(1)   10,000    10,000 
Total senior secured principal  $382,982   $760,000 
2026 Notes   1,225,000    – 
Notes offered hereby(2)   –    850,000 
Other debt(3)   48,721    48,721 
Total debt principal outstanding  $1,656,703   $1,658,721 
Unamortized discount   9,346    (1,875)
Unamortized debt issuance costs   (6,654)   (24,775)
Total debt  $1,659,395   $1,632,071 
           
Total stockholders’ equity   1,688,127    1,688,127 
Total capitalization   3,347,522    3,320,198 
           
Total net debt principal outstanding   1,602,057    1,631,399 
Total net senior secured principal   328,336    732,678 

 

 

(1)            The revolving loan under our senior secured credit facilities provides for borrowings of up to $600.0 million of which $546.6 million was available as of September 30, 2024, for working capital and general corporate purposes (after given effect to the Refinancing Transactions and to $43.4 million of outstanding letters of credit at September 30, 2024).

 

(2)            Represents the aggregate principal amount of the notes being offered and does not reflect initial purchaser discounts and debt issuance costs.

 

(3)            Other debt consists primarily of borrowings to finance insurance programs, indebtedness to sellers of acquired businesses and other miscellaneous borrowings.

 

 

 

 

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

 

The following unaudited pro forma consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, are presented as if the Separation and the Refinancing Transactions occurred as of January 1, 2023. The adjustments in the “Transaction Accounting Adjustments” column in the unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, give effect to the Separation as if it occurred as of January 1, 2023. The adjustments in the “Refinancing Transaction Adjustments” column in the unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, give effect to the Refinancing Transactions as if the Refinancing Transactions occurred as of January 1, 2023. The following unaudited pro forma consolidated balance sheet as of September 30, 2024 is presented as if Separation and the Refinancing Transactions occurred on September 30, 2024.

 

The following unaudited pro forma consolidated financial information has been derived from our historical consolidated financial statements as of and for the year ended December 31, 2023 and the interim unaudited period ended September 30, 2024. The unaudited pro forma consolidated financial information and the accompanying notes should be read in conjunction with (i) the audited consolidated financial statements, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2023, and (ii) the unaudited consolidated financial statements, the accompanying notes, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

 

The following unaudited pro forma financial information is based on information currently available, including certain assumptions and estimates. They are intended for informational purposes only, and do not purport to represent what our financial position and results of operations actually would have been had the Separation occurred on the dates indicated, or to project our financial position or results of operations for any future date or period. The adjustments included with the “Concentra Discontinued Operations” column of the unaudited pro forma condensed consolidated financial information is the current estimates on a discontinued operations basis and could change as our finalized discontinued operations accounting to be reported in future periods once the Separation occurs.

 

The preliminary financial data included in this offering memorandum has been prepared by, and is the responsibility of, Select’s management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

 

 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Nine Months Ended September 30, 2024

(in thousands, except per share data)

 

  

Select Medical Holdings
Corporation Historical

(As Reported)

   Concentra Discontinued
Operations
(Note a)		   Continuing
Operations		   Transaction
Accounting
Adjustments		   Refinancing
Transactions Impact		   Pro Forma Select
Medical Holdings
Corporation		 
Revenue  $5,309,692   $(1,435,151)  $3,874,541   $—   $       —   $3,874,541 
Costs and expenses:                              
Cost of services, exclusive of depreciation and amortization   4,516,553    (1,136,622)   3,379,931    —    —    3,379,931 
General and administrative   145,672    (1,569)   144,103    —    —    144,103 
Depreciation and amortization   158,151    (51,568)   106,583    —    —    106,583 
Total costs and expenses   4,820,376    (1,189,759)   3,630,617    —    —    3,630,617 
Other operating income   3,584    (284)   3,300    —    —    3,300 
Income from operations   492,900    (245,676)   247,224    —    —    247,224 
Other income and expense:                              
Loss on early retirement of debt   (10,939)   —    (10,939)   10,939(b)   —    — 
Equity in earnings of unconsolidated subsidiaries   49,805    3,676    53,481    —    —    53,481 
Interest expense   (143,309)   43,255    (100,054)   35,965(b)   815(d)   (63,274)
Income before income taxes   388,457    (198,745)   189,712    46,904    815    237,431 
Income tax expense   95,509    (46,241)   49,268    12,444(c)   216(e)   61,928 
Net income   292,948    (152,504)   140,444    34,460    599    175,503 
Less: Net income attributable to non-controlling interests   62,860    (11,554)   51,306    —    —    51,306 
Net income attributable to Select Medical Holdings Corporation  $230,088   $(140,950)  $89,138   $34,460   $599   $124,197 
Earnings per common share:                              
Basic and diluted  $1.78                       $0.96 
Weighted average shares outstanding                              
Basic and diluted   129,192                        129,192 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2023

(in thousands, except per share data)

 

  

Select Medical Holdings
Corporation Historical

(As Reported)

   Concentra Discontinued
Operations
(Note a)		  

Continuing

Operations

   Transaction
Accounting
Adjustments		   Refinancing
Transactions
Impact		   Pro Forma Select
Medical Holdings
Corporation		 
Revenue  $6,664,058   $(1,838,081)  $4,825,977   $—   $—   $4,825,977 
Costs and expenses:                              
Cost of services, exclusive of depreciation and amortization   5,732,017    (1,477,648)   4,254,369    —    —    4,254,369 
General and administrative   170,193    —    170,193    —    —    170,193 
Depreciation and amortization   208,742    (73,051)   135,691    —    —    135,691 
Total costs and expenses   6,110,952    (1,550,699)   4,560,253    —    —    4,560,253 
Other operating income   1,768    (250)   1,518              1,518 
Income from operations   554,874    (287,632)   267,242    —    —    267,242 
Other income and expense:                              
Loss on early retirement of debt   (14,692)   —    (14,692)   (10,939)(b)   (9,722)(d)   (35,353)
Equity in earnings of unconsolidated subsidiaries   40,813    526    41,339    —    —    41,339 
Interest (expense) income   (198,639)   44,474    (154,165)   169,668(b)   2,951(d)   18,454 
Income before income taxes   382,356    (242,632)   139,724    158,729    (6,771)   291,682 
Income tax expense   82,625    (53,372)   29,253    42,111(c)   (1,796)(e)   69,568 
Net income   299,731    (189,260)   110,471    116,618    (4,975)   222,114 
Less: Net income attributable to non-controlling interests   56,240    (4,796)   51,444    —    —    51,444 
Net income attributable to Select Medical Holdings Corporation  $243,491   $(184,464)  $59,027   $116,618   $(4,975)  $170,670 
Earnings per share:                              
Basic and diluted  $1.91                       $1.34 
Weighted average shares outstanding                              
Basic and diluted   127,706                        127,706 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of September 30, 2024

(in thousands)

 

   Select Medical Holdings
Corporation Historical
(As Reported)		   Concentra Discontinued
Operations
(Note a)		   Refinancing Transaction
Adjustments		   Pro Forma Select Medical
Holdings Corporation		 
ASSETS                    
Current Assets:                    
Cash and cash equivalents  $191,468   $(136,822)  $(27,324)(d)  $27,322 
Accounts receivable   1,060,007    (232,202)   —    827,805 
Prepaid income taxes   8,669    (1,505)   —    7,164 
Other current assets   144,053    (23,041)   —    121,012 
Total Current Assets   1,404,197    (393,570)   (27,324)   983,303 
Operating lease right-of-use assets   1,321,045    (430,133)   —    890,912 
Property and equipment, net   1,040,383    (191,099)   —    849,284 
Goodwill   3,555,022    (1,234,707)   —    2,320,315 
Identifiable intangible assets, net   312,565    (209,171)   —    103,394 
Other assets   369,449    (5,975)   —    363,474 
Total Assets  $8,002,661   $(2,464,655)  $(27,324)  $5,510,682 
LIABILITIES AND EQUITY                    
Current Liabilities:                    
Overdrafts  $14,173   $—   $—   $14,173 
Current operating lease liabilities   249,832    (74,411)   —    175,421 
Current portion of long-term debt and notes payable   42,785    (9,737)   7,500(d)   40,548 
Accounts payable   170,711    (21,030)   —    149,681 
Accrued and other liabilities   768,203    (147,956)   —    620,247 
Total Current Liabilities   1,245,704    (253,134)   7,500    1,000,070 
Non-current operating lease liabilities   1,163,406    (391,037)   —    772,369 
Long-term debt, net of current portion   3,098,957    (1,472,610)   (34,824)(d)   1,591,523 
Non-current deferred tax liability   95,557    (22,454)   —    73,103 
Other non-current liabilities   98,593    (24,188)   —    74,405 
Total Liabilities   5,702,217    (2,163,423)   (27,324)   3,511,470 
Redeemable non-controlling interests   30,455    (18,122)   —    12,333 
Stockholders’ Equity:                    
Common stock   130    —    —    130 
Capital in excess of par   858,741    —    —    858,741 
Retained earnings   1,056,320    (227,064)   —    829,256 
Total Stockholders’ Equity   1,915,191    (227,064)   —    1,688,127 
Non-controlling interests   354,798    (56,046)   —    298,752 
Total Equity   2,269,989    (283,110)   —    1,986,879 
Total Liabilities and Equity  $8,002,661   $(2,464,655)  $(27,324)  $5,510,682 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

Concentra Discontinued Operations:

 

(a)Reflects the anticipated discontinued operations of Concentra, including associated assets, liabilities, and equity and results of operations in accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations as currently estimated.

 

Transaction Accounting Adjustments:

 

(b)Reflects the estimated reduced interest expense of $82.0 million for the nine months ended September 30, 2024 and $123.7 million for the year ended December 31, 2023, respectively, as a result of the payments made with the cash proceeds received in connection with the Concentra Separation to reduce long-term debt obligations. Additionally, the estimated reduced interest expense for the year-ended December 31, 2023 reflects a reclassification of a $46.0 million gain on the interest rate cap cash flow hedge from accumulated other comprehensive income into interest expense for forecasted transactions that were probable not to occur as of that date, which was reported in the historical results for the nine months ended September 30, 2024.

 

As a result of the repayments, a loss on extinguishment of debt related to the write-off of unamortized deferred financing fees of $10.9 million for the year ended December 31, 2023 is also reflected, which was reported in the historical results for the nine months ended September 30, 2024.

 

(c)Reflects the tax effects of the Transaction Accounting Adjustments to pre-tax book income at the applicable statutory income tax rates.

 

Refinancing Transaction Adjustments:

 

(d)Reflects the impacts of the Refinancing Transactions, which include the estimated reduced interest expense of $0.8 million for the nine months ended September 30, 2024 and $2.9 million for the year ended December 31, 2023, respectively, as a result of lower interest rates on the refinanced debt. With respect to the Refinancing Transactions, the pro forma financial information includes the following assumptions:

 

·Refinancing Term Loans in an aggregate principal amount of $750.0 million bearing interest at a rate equal to SOFR + 2.00% and an original issue discount of $1.9 million;
·$850.0 million of Senior Notes due 2032 bearing interest at a rate equal to 6.25%; and
·Estimated debt issuance costs of $24.3 million.

 

The net proceeds of this offering, together with the proceeds from the Refinancing Term Loans and $27.3 million of cash on hand, will be used to repay in full the Existing Select Term Loan, to redeem all of the 2026 Notes (including an estimated call premium of $12.8 million) and to pay fees and expenses related to the foregoing. The Refinancing Transactions are assumed to qualify for debt extinguishment accounting resulting in a $9.7 million loss on early retirement of debt (inclusive of the $12.8 million call premium noted above) and the capitalization of new debt issuance costs.

 

A variance of 1/8% of the weighted average interest rate estimate would result in a $2.0 million change in annual cash interest expense associated with the $1,600.0 million of indebtedness expected to be incurred.

 

(e)Reflects the tax effects of the Refinancing Transaction Adjustments to pre-tax book income at the applicable statutory income tax rates.